Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire

NEW YORK, October 30, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Shire PLC (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7560-100free.

--
Merck & Co., Inc. Research Reports
On October 27, 2014, Merck & Co., Inc. (Merck) reported 4.3% YoY decline in Q3 2014 sales to $10.56 billion. Merck's Pharmaceutical revenue declined 3.6% YoY to $9.1 billion, due to the ongoing impact of product divestitures, as well as the loss of market exclusivity for certain products. Revenue from Animal Health increased 11% YoY, while Consumer Care sales decreased 9% YoY. Q3 2014 net income attributable to Merck came in at $895 million or $0.31 per diluted share, compared to $1.1 billion or $0.38 per diluted share in Q3 2013. Non-GAAP EPS was $0.90 compared to $0.92 in Q3 2013. On average, 18 analysts polled by Thomson Reuters expected the Company to report EPS (excluding special items) of $0.88 on revenue of $10.67 billion. The Company's 9M 2014 sales declined 2.9% YoY to $31.8 billion, while net income attributable to Merck improved 27.1% YoY to $4.6 billion. For full-year 2014, the Company expects revenues between $42.4 billion and $42.8 billion and GAAP EPS in the range of $4.06 - $4.29. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/MRK/report.pdf

--
Johnson & Johnson Research Reports
On October 22, 2014, Johnson & Johnson (Johnson & Johnson) announced that the Company has made a new commitment of up to $200 million to speed up and significantly expand the production of an Ebola vaccine program in development at Janssen Pharmaceutical Companies (Janssen), a subsidiary of Johnson & Johnson. The Company informed that the vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health (NIH), combines a Janssen preventative vaccine with a vaccine from Bavarian Nordic, a biotechnology company based in Denmark. The Company stated that Janssen aims to produce more than one million doses of the vaccine regimen in 2015, of which 250,000 are expected to be released for broad application in clinical trials by May 2015. The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/JNJ/report.pdf

--
Amgen, Inc. Research Reports
On October 27, 2014, Amgen, Inc. (Amgen) released its Q3 2014 and 9M 2014 financial results. The Company reported Q3 2014 total revenues of $5.03 billion, up 6.0% YoY, led by 4.3% YoY improvement in product sales to $4.8 billion due to strong performance across the portfolio, particularly Kyprolis® (carfilzomib), Prolia® (denosumab), Neulasta® (pegfilgrastim) and XGEVA® (denosumab). The Company posted Q3 2014 net income of $1.2 billion, compared to $1.4 billion in Q3 2013. Amgen's adjusted EPS grew 19% YoY to $2.30. Analysts polled by Thomson Reuters expected a per-share profit of $2.11 and revenue of $4.96 billion. The Company reported 9M 2014 total revenues of $14.7 billion, up 7.8% YoY, and net income of $3.9 billion, down 4.8% YoY. The Company expects full-year 2014 revenues in the range of $19.8 - $20 billion and adjusted EPS in the range of $8.45 - $8.55. The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/AMGN/report.pdf

--
Medtronic, Inc. Research Reports
On October 21, 2014, Medtronic, Inc. (Medtronic) announced that it has launched the DIVERGENCE(TM) Anterior Cervical Fusion System in the U.S. for the treatment of single-level cervical disc disease at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting in Boston. The Company informed that the DIVERGENCE(TM) System represents a new approach to one-level anterior cervical discectomy with fusion (ACDF) procedures, which traditionally use a four-hole plate and interbody fusion cage. Further, with the use of DIVERGENCE(TM) System, the plate and interbody cage can be inserted simultaneously using a common set of instrumentation and one surgical technique. In addition, the DIVERGENCE(TM) System incorporates a laterally-divergent screw insertion technique, requiring less retraction versus the traditional medially-convergent screw insertion techniques used with other anterior cervical plating systems. The full research reports on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/MDT/report.pdf

--
Shire PLC Research Reports
On October 27, 2014, Shire PLC (Shire) issued a press release in accordance with the 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules. Shire informed that its Chairman, Susan Kilsby, acquired 2,500 American Depositary Shares ("ADSs") of the Company on October 24, 2014 at an average price of $194.4264 per ADS. Post the transaction, Ms. Kilsby holds 3,041 ADSs. One ADS is equal to three ordinary shares of 5 pence each in the Company. The full research reports on Shire are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/SHPG/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review